Lixte Biotechnology Reports $1.99M Net Loss and No Revenue for Q1 2026

Lixte Biotechnology Holdings, Inc. reported a net loss of $1,987,608 for the three months ended March 31, 2026, compared to a net loss of $709,555 for the same period in 2025. The company did not generate any revenue during this period. Total costs and expenses surged to $1,987,407, a significant increase from $706,940 in the prior year, primarily driven by a 265% rise in research and development costs, which reached $333,376, and a 169% increase in general and administrative expenses, totaling $1,654,031. The increase in expenses was attributed to higher accounting, investment banking, and public relations fees, as well as costs associated with the acquisition of Liora Technologies Europe Ltd.

As of March 31, 2026, Lixte's total assets were valued at $10,865,298, down from $12,733,621 at the end of 2025. The decrease was primarily due to a reduction in cash reserves, which fell to $3,250,650 from $5,106,872. The company's liabilities also decreased to $1,686,706 from $1,772,070, reflecting a reduction in accounts payable and accrued expenses. Stockholders' equity decreased to $9,178,592 from $10,961,551, largely due to the net loss incurred during the quarter.

Strategically, Lixte has focused on advancing its clinical-stage product candidate, LB-100, which is currently undergoing trials for various cancer indications. The company is also in the process of recommissioning and updating its LiGHT proton therapy system, which is expected to incur approximately $2 million in costs over the next 24 months. The acquisition of Liora Technologies, completed in late 2025, has positioned Lixte to enhance its capabilities in cancer treatment technologies, although Liora currently has no revenue-generating operations.

The company continues to face significant financial challenges, as it has not yet commenced revenue-generating operations and relies heavily on external financing to fund its activities. Management has expressed substantial doubt regarding the company's ability to continue as a going concern for at least the next 12 months, given its ongoing losses and reliance on capital markets for funding. Lixte is actively exploring various financing alternatives, including equity and debt financing, to support its operations and clinical development programs.

Looking ahead, Lixte's management remains focused on advancing its clinical trials and exploring strategic partnerships to enhance its product pipeline. However, the company acknowledges the inherent risks and uncertainties associated with drug development, including regulatory approvals and market acceptance, which could significantly impact its future financial performance and operational viability.